[{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Cibotercept","moa":"ACVR2B","graph1":"Hematology","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"iCell Gene Therapeutics","sponsor":"iCell ImmunityX","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"BCMA-CD19 cCAR-T Cell","moa":"B-cell maturation antigen\/CD19","graph1":"Hematology","graph2":"Phase I","graph3":"iCell Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"iCell Gene Therapeutics \/ iCell ImmunityX","highestDevelopmentStatusID":"6","companyTruncated":"iCell Gene Therapeutics \/ iCell ImmunityX"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP-7041","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"MK-2060","moa":"Coagulation factor XI (F11)","graph1":"Hematology","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"STP122G","moa":"Factor XI","graph1":"Hematology","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirnaomics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Undisclosed"},{"orgOrder":0,"company":"Kashiv BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"TPI-120","moa":"Granulocyte colony stimulating factor receptor","graph1":"Hematology","graph2":"Phase I","graph3":"Kashiv BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kashiv BioSciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kashiv BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"DISC-0974","moa":"Hemojuvelin","graph1":"Hematology","graph2":"Phase I","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Disc medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Disc medicine \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Bond Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BBI-001","moa":"Iron absorption","graph1":"Hematology","graph2":"Phase I","graph3":"Bond Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Bond Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bond Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Blueprint Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"BLU-263","moa":"KIT","graph1":"Hematology","graph2":"Phase I","graph3":"Blueprint Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Blueprint Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Blueprint Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Zaltenibart","moa":"MASP1","graph1":"Hematology","graph2":"Phase I","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Acrotech Biopharma","sponsor":"Axis Clinicals Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Vincristine Sulfate","moa":"Tubulin","graph1":"Hematology","graph2":"Phase I","graph3":"Acrotech Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Acrotech Biopharma \/ Axis Clinicals Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Acrotech Biopharma \/ Axis Clinicals Ltd."},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ANX1502","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Annexon Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Annexon Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Spray","sponsorNew":"Velico Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Undisclosed"},{"orgOrder":0,"company":"Immune Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KQ-2003","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Immune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immune Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Immune Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rallybio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"RLYB116","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Rallybio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rallybio \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Rallybio \/ Undisclosed"},{"orgOrder":0,"company":"Velico Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Spray-Dried Plasma","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Velico Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Velico Medical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Velico Medical \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sirius Therapeutics","sponsor":"BioTrack Capital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"SRSD107","moa":"Undisclosed","graph1":"Hematology","graph2":"Phase I","graph3":"Sirius Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Sirius Therapeutics \/ BioTrack Capital","highestDevelopmentStatusID":"6","companyTruncated":"Sirius Therapeutics \/ BioTrack Capital"},{"orgOrder":0,"company":"eXIthera Pharmaceutical","sponsor":"Cadrenal Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Frunexian","moa":"F11a","graph1":"Hematology","graph2":"Phase I","graph3":"eXIthera Pharmaceutical","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"eXIthera Pharmaceutical \/ Cadrenal Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
